CRISPR Therapeutics AG

CRISPR Therapeutics AG faces a pivotal moment: Q1 2026 earnings dip, but revenue growth signals clinical traction; investors eye the Bank of America Healthcare Conference for a turnaround strategy, with its base‑editing tech poised to leverage risin…

CRISPR‑Therapeutics faces a pivotal patent battle as the PTAB rules in favor of the Broad Institute, threatening its gene‑editing pipeline and investor confidence.

CRISPR Therapeutics AG (CRSP) gains investor optimism as the $8.74 billion gene‑transfer market expands, with analysts backing its cutting‑edge gene‑editing pipeline.